1-4 of 4
Jay T. Backstrom, MD
Close
Sort by
Journal Articles

Hematologic Improvement, Transfusion Independence, and Safety Assessed Using Three Alternative Dosing Schedules of Azacitidine in Patients with Myelodysplastic Syndromes.

Roger M. Lyons, MD, Thomas Cosgriff, MD, Sanjiv Modi, MD, Heidi McIntyre, BA, C.L. Beach, PharmD, Jay T. Backstrom, MD, MPH
Journal: Blood
Blood (2006) 108 (11): 2662.
https://doi.org/10.1182/blood.V108.11.2662.2662
Published: 2006
Journal Articles

Rates of Infection and Bleeding Are Not Increased in Patients with Myelodysplastic Syndromes (MDS) Treated with Azacitidine Compared with Supportive Care.

Lewis R. Silverman, MD, David R. McKenzie, MS, Bercedis L. Peterson, PhD, Rosalie Odchimar-Reissig, RN, MSN, CCRC, Randy Hinkle, RPh, Jay T. Backstrom, MD, Richard A. Larson, MD, The Cancer Leukemia Group B (CALGB).
Journal: Blood
Blood (2005) 106 (11): 2525.
https://doi.org/10.1182/blood.V106.11.2525.2525
Published: 2005
Journal Articles

Azacitidine (Vidaza®) Treatment Response Assessed Using Three Alternative Dosing Schedules in Patients with Myelodysplastic Syndromes (MDS).

Roger Lyons, MD, Thomas Cosgriff, MD, Sanjiv Modi, MD, Linda Lintz, BA, C.L. Beach, PharmD, Jay T. Backstrom, MD, MPH
Journal: Blood
Blood (2005) 106 (11): 2517.
https://doi.org/10.1182/blood.V106.11.2517.2517
Published: 2005
Journal Articles

Response Rates in Patients with Acute Myeloid Leukemia (AML), Treated with Azacitidine, Using WHO and International Working Group (IWG) Criteria for Myelodysplastic Syndrome (MDS).

Lewis R. Silverman, MD, David R. McKenzie, MS, Bercedis L. Peterson, PhD, Richard M. Stone, MD, Bayard L. Powell, MD, Christy Mayo, MS, Jay T. Backstrom, MD, MPH, Richard A. Larson, MD, The Cancer Leukemia Group B (CALGB)
Journal: Blood
Blood (2005) 106 (11): 1848.
https://doi.org/10.1182/blood.V106.11.1848.1848
Published: 2005